NCT06899906
- Conditions
- Efficacy and Safety of Dalbavancin, For Acute or Chronic Infections Between July 2019 and December 2024, In Subjects Who Received SAT with DAL
- Locations
-
- HCL France, Lyon
Clinical trial condition
In Subjects Who Received SAT with DAL
Explore clinical trials studying In Subjects Who Received SAT with DAL. Study availability and eligibility vary by location and protocol.
1 public trial
1 recruiting study